Mobile

An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately respondi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003976-39

An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately responding to a 5 week therapy with ramipril 5 mg and felodipine 5 mg

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that 5 weeks of treatment with valsartan 160 mg plus amlodipine 10 mg provide an additional mean sitting systolic blood pressure reduction in patients not adequately responding to 5 weeks of treatment with ramipril 5 mg and felodipine 5 mg (i.e., MSSBP ≥ 140 mmHg).

Critère d'inclusion

  • Patients with essential hypertension

Liens